lilly self pay tirzepatide Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program Eli Lilly Adds Highest Doses

Risk of falls is markedly higher Risk of fractures may be further increased when cardiovascular disease is present Our new systematic review just published in Current Osteoporosis Reports, explores fracture risk in T2D within large cardiovascular outcome trials of GLP-1 receptor agonists

The buttocks are not an FDA-approved injection site for tirzepatide

2022;131(3):e70-e82

For more information, see this Trulicity interactions article

And while the aforementioned JAMA and EMA reviews have provided stepping stones to better understanding the risks involved with the drug, further research continues to investigate the causal links between GLP-1 and NAION and nAMD development.